The Compound — Research
What is retatrutide?
Semaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits three — and the third one does something the others cannot. Here is what the Phase 2 data showed and what it does not yet tell us.
Three generations of GLP-1 drugs
Semaglutide, the molecule inside Ozempic and Wegovy, activates one receptor: GLP-1. It slows gastric emptying, triggers insulin release, and quiets appetite signals in the brain. It was genuinely transformative for millions of people. But it only works on one side of the energy equation — it cuts what you eat, but it does nothing to raise what you burn.
Tirzepatide added a second receptor, GIP. The combination proved stronger than either alone. GIP amplifies the weight loss effect and helps reduce the nausea that often comes with GLP-1 agonism. Clinical trials showed roughly 20–22% weight loss — a meaningful jump over semaglutide.
Retatrutide adds a third: glucagon.
What glucagon actually does here
Glucagon normally raises blood sugar — that is its primary job. Glucagon receptors sit almost entirely in the liver. Activate them, and the liver starts burning fatty acids directly, raising resting energy expenditure. The body burns more fuel at baseline, even while you are still or asleep.
The obvious concern: if glucagon raises blood sugar, adding a glucagon agonist to a weight loss drug sounds dangerous. Retatrutide was designed around this problem. It hits GIP at about nine times the potency of the natural hormone, with weaker activity at GLP-1 and glucagon. The insulin released by GLP-1 and GIP offsets glucagon's glucose-raising effect. You get the fat-burning and increased energy expenditure without the blood sugar spike. Nothing else in the class does this.
What the Phase 2 trial found
The 2023 Phase 2 trial enrolled 338 adults with obesity. The 12mg group lost an average of 24.2% of their body weight by week 48. What drew attention was not just the number — it was the shape of the curve. The weight loss had not plateaued by week 48. It was still falling.
The weight loss was not the most striking finding.
A 2024 substudy showed an 86% drop in liver fat, with 93% of participants returning to normal. 72% of prediabetics returned to normal blood sugar levels. Fatty liver disease affects roughly 40% of the global population. Telling someone to just lose weight rarely moves liver fat this dramatically.
Behavioral effects and reward circuits
Users and clinicians have reported that retatrutide reduces compulsive behaviors — alcohol, gambling, excessive scrolling. This matches what has been observed with semaglutide and tirzepatide at a lower level: GLP-1 receptors sit in brain regions that govern reward and craving, and activating them damps dopaminergic signaling in those circuits.
The evidence for this is largely anecdotal in the context of retatrutide specifically. The mechanism is plausible and there is growing RCT evidence for GLP-1s and alcohol reduction specifically, but retatrutide has not been formally studied for addiction. This is an area of active research, not a proven indication.
Where it stands now
Current status
- Phase 3 trials ongoing
- Eli Lilly regulatory submission expected 2026
- Not FDA-approved — the only legal route is a clinical trial
- FDA actively pursuing gray-market vendors
- Unknown behavior past 68 weeks
If Phase 3 confirms what Phase 2 showed, retatrutide will be the most effective FDA-approved weight loss drug in history. Tirzepatide, its predecessor, is already the highest-selling drug in the world. The market for a triple agonist with better numbers is considerably larger.
The responsible path right now: tirzepatide is approved, available, and produces clinically significant results. If you need treatment today, that is what exists today. For a full comparison on efficacy, side effects, and timeline, see retatrutide vs tirzepatide, or see how retatrutide stacks up against Novo Nordisk's competing bet in retatrutide vs CagriSema.
